

# Renata Zadro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7942333/publications.pdf>

Version: 2024-02-01

44  
papers

798  
citations

687363

13  
h-index

526287

27  
g-index

44  
all docs

44  
docs citations

44  
times ranked

1568  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cellular Immunityâ€”The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination. <i>Vaccines</i> , 2022, 10, 442.	4.4	21
2	Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVIDâ€“19 patients: A pilot study. <i>Journal of Medical Virology</i> , 2022, 94, 3669-3675.	5.0	13
3	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. <i>Leukemia</i> , 2022, 36, 1834-1842.	7.2	10
4	Allele and haplotype frequencies of P-selectin gene in Croatian population and review of literature. , 2022, 33, 201056.		0
5	Overall hemostasis potential and aPTTâ€“elot waveform analysis as powerful laboratory diagnostic tools for identification of hemophilia A patients with unexpected bleeding phenotype. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 273-280.	1.3	7
6	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
7	Analytical validation of the iSED automated analyzer for erythrocyte sedimentation rate. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 109-115.	1.3	6
8	Role of platelet gene polymorphisms in ischemic pediatric stroke subtypes: a case-control study. <i>Croatian Medical Journal</i> , 2020, 61, 18-27.	0.7	7
9	Verification of automated latex-enhanced particle immunoturbidimetric D-Dimer assays on different analytical platforms and comparability of test results. <i>Biochemia Medica</i> , 2020, 30, 457-465.	2.7	6
10	Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1645-1650.	2.5	10
11	Influence of flavonoidsâ€™ lipophilicity on platelet aggregation. <i>Acta Pharmaceutica</i> , 2019, 69, 607-619.	2.0	5
12	Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 53-63.	0.4	24
13	Development and validation of a rapid method for genotyping three Pâ€“selectin gene polymorphisms based on high resolution melting analysis. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22698.	2.1	3
14	Autovalidation and automation of the postanalytical phase of routine hematology and coagulation analyses in a university hospital laboratory. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 454-462.	2.3	11
15	The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML). <i>Blood Research</i> , 2018, 53, 152.	1.3	3
16	Serum chitotriosidase: a circulating biomarker in polycythemia vera. <i>Hematology</i> , 2018, 23, 793-802.	1.5	4
17	Association of Polymorphisms in Coagulation Factor Genes and Enzymes of Homocysteine Metabolism With Arterial Ischemic Stroke in Children. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 1042-1051.	1.7	27
18	Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 472-476.	0.4	11

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2281-2288.	1.3	9
20	Implementation of NIH Criteria for Standardization of Chronic Graft-Versus-Host Disease in Croatia: Two-Year Experience. <i>Blood</i> , 2015, 126, 5580-5580.	1.4	0
21	Comparison of the Impact of Four Generations of Progestins on Hemostatic Variables. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2014, 20, 448-455.	1.7	12
22	Routine Tests of Haemostasis and Low-Oestrogen Oral Contraceptives: What to Expect?. <i>Clinical Laboratory</i> , 2014, 60, 827-32.	0.5	0
23	Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity. <i>International Orthopaedics</i> , 2013, 37, 529-541.	1.9	26
24	Multiple presence of prothrombotic risk factors in Croatian children with arterial ischemic stroke and transient ischemic attack. <i>Croatian Medical Journal</i> , 2013, 54, 346-354.	0.7	7
25	Inherited prothrombotic risk factors in children with first ischemic stroke. <i>Biochemia Medica</i> , 2012, 22, 298-310.	2.7	19
26	Bone morphogenetic protein-7 expression is down-regulated in human clear cell renal carcinoma. <i>Journal of Nephrology</i> , 2011, 24, 91-97.	2.0	7
27	Pre-B cell acute lymphoblastic leukemia with bulk extramedullary disease and chromosome 22 (EWSR1) rearrangement masquerading as Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2010, 54, 606-609.	1.5	15
28	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. <i>Blood</i> , 2010, 116, 894-894.	1.4	1
29	Inherited Prothrombotic Risk Factors in Children With Stroke, Transient Ischemic Attack, or Migraine. <i>Pediatrics</i> , 2009, 123, e653-e660.	2.1	47
30	Evaluation of the Innovance D-DIMER analytical performance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 945-51.	2.3	26
31	Immunolocalization and mRNA Expression of Bone Morphogenetic Protein-6 in Human Clear Cell Renal Carcinoma. <i>Kidney and Blood Pressure Research</i> , 2009, 32, 445-450.	2.0	8
32	Impact of FXIII-A Val34Leu polymorphism on coronary artery disease in Croatian patients. <i>Molecular Biology Reports</i> , 2009, 36, 1-5.	2.3	14
33	Lower Contribution of Factor V Leiden or G202104 Mutations to Ischemic Stroke in Patients With Clinical Risk Factors. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2007, 13, 188-193.	1.7	9
34	The External RNA Controls Consortium: a progress report. <i>Nature Methods</i> , 2005, 2, 731-734.	19.0	328
35	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 862-8.	2.3	3
36	IgH and TCRgamma Gene Rearrangements, Cyclin A1 and HOXA9 Gene Expression in Biphenotypic Acute Leukemias.. <i>Blood</i> , 2005, 106, 4472-4472.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Acute Promyelocytic Leukemia M3: Cytomorphologic, Immunophenotypic, Cytogenetic, and Molecular Variants. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 941-950.	1.8	27
38	Temporal Pattern of Stimulation of Osteoblast-Associated Genes During Mechanically-Induced Osteogenesis <i>&lt;i&gt;In Vivo&lt;/i&gt;</i> : Early Responses of Osteocalcin and Type I Collagen. <i>Connective Tissue Research</i> , 2001, 42, 135-148.	2.3	55
39	Double Immunoenzymatic APAAP Staining for the Detection of Leukemia-Associated Immunophenotypes. <i>Journal of Hematotherapy and Stem Cell Research</i> , 1999, 8, 635-643.	1.8	3
40	Analysis of Clonality in T-Lymphoproliferative Diseases by Multiplex PCR. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 637-9.	2.3	0
41	074 Hepatopoietin-like activity in patients with liver disease. <i>Fresenius' Journal of Analytical Chemistry</i> , 1992, 343, 132-133.	1.5	1
42	Dependence of diffusion coefficients and immunoprecipitating titers on pH: Human serum transferrin, immunoglobulin A, human chorionic somatomammotropin, and their rabbit antibodies. <i>Analytical Biochemistry</i> , 1981, 117, 238-244.	2.4	6
43	Clinical significance of T315I ABL kinase domain mutation detection in patients resistant to imatinib mesylate therapy. <i>Biochemia Medica</i> , 0, , 75-81.	2.7	1
44	Monitoring chronic myeloid leukemia patients responding to treatment with tyrosine kinase inhibitors by real-time quantitative polymerase chain reaction. <i>Biochemia Medica</i> , 0, , 63-72.	2.7	0